Hillhouse Capital Management Ltd. Has $7.19 Million Holdings in Nabriva Therapeutics AG (NBRV)
Hillhouse Capital Management Ltd. decreased its holdings in shares of Nabriva Therapeutics AG (NASDAQ:NBRV) by 0.1% in the second quarter, according to the company in its most recent Form 13F filing with the Securities & Exchange Commission. The firm owned 686,400 shares of the biotechnology company’s stock after selling 500 shares during the period. Hillhouse Capital Management Ltd. owned about 2.56% of Nabriva Therapeutics AG worth $7,193,000 as of its most recent SEC filing.
A number of other institutional investors and hedge funds have also made changes to their positions in the business. Royal Bank of Canada grew its stake in shares of Nabriva Therapeutics AG by 19.6% in the 2nd quarter. Royal Bank of Canada now owns 52,807 shares of the biotechnology company’s stock valued at $553,000 after purchasing an additional 8,650 shares during the period. Nationwide Fund Advisors lifted its position in shares of Nabriva Therapeutics AG by 4.6% during the 2nd quarter. Nationwide Fund Advisors now owns 180,924 shares of the biotechnology company’s stock worth $2,032,000 after buying an additional 7,924 shares during the period. Almanack Investment Partners LLC. lifted its position in shares of Nabriva Therapeutics AG by 482.2% during the 2nd quarter. Almanack Investment Partners LLC. now owns 907,183 shares of the biotechnology company’s stock worth $1,633,000 after buying an additional 751,366 shares during the period. Finally, Wellington Management Group LLP lifted its position in shares of Nabriva Therapeutics AG by 9.9% during the 1st quarter. Wellington Management Group LLP now owns 2,154,261 shares of the biotechnology company’s stock worth $25,830,000 after buying an additional 193,951 shares during the period. Hedge funds and other institutional investors own 67.60% of the company’s stock.
A number of analysts have weighed in on the company. Zacks Investment Research upgraded Nabriva Therapeutics AG from a “hold” rating to a “buy” rating and set a $12.00 price target on the stock in a research report on Thursday, August 10th. Cantor Fitzgerald restated an “overweight” rating on shares of Nabriva Therapeutics AG in a research note on Friday, June 23rd. ValuEngine downgraded shares of Nabriva Therapeutics AG from a “hold” rating to a “sell” rating in a research note on Tuesday, August 1st. HC Wainwright reaffirmed a “buy” rating and issued a $16.00 target price on shares of Nabriva Therapeutics AG in a report on Friday, June 30th. Finally, Leerink Swann reiterated an “outperform” rating and set a $22.00 target price (up previously from $20.00) on shares of Nabriva Therapeutics AG in a research report on Monday, September 18th. One investment analyst has rated the stock with a sell rating, one has given a hold rating and seven have issued a buy rating to the company’s stock. Nabriva Therapeutics AG presently has an average rating of “Buy” and a consensus price target of $19.13.
In other Nabriva Therapeutics AG news, major shareholder Hbm Healthcare Investments (Ca sold 57,175 shares of the business’s stock in a transaction on Thursday, July 13th. The shares were sold at an average price of $10.53, for a total transaction of $602,052.75. Following the sale, the insider now owns 2,565,661 shares of the company’s stock, valued at $27,016,410.33. The transaction was disclosed in a legal filing with the SEC, which is accessible through this link. Also, major shareholder Vivo Capital Viii, Llc purchased 52,631 shares of the stock in a transaction dated Monday, September 18th. The shares were bought at an average price of $9.46 per share, with a total value of $497,889.26. The disclosure for this purchase can be found here. Over the last quarter, insiders have purchased 57,219 shares of company stock valued at $535,919 and have sold 255,540 shares valued at $2,614,045. 2.75% of the stock is owned by corporate insiders.
Nabriva Therapeutics AG (NBRV) traded up 1.80% on Wednesday, reaching $8.48. 348,686 shares of the company traded hands. The stock has a 50-day moving average of $8.55 and a 200 day moving average of $9.93. Nabriva Therapeutics AG has a 52-week low of $3.52 and a 52-week high of $14.10. The company’s market capitalization is $227.59 million.
Nabriva Therapeutics AG (NASDAQ:NBRV) last posted its earnings results on Monday, August 7th. The biotechnology company reported ($0.54) EPS for the quarter, topping analysts’ consensus estimates of ($5.83) by $5.29. The company had revenue of $1.05 million during the quarter, compared to the consensus estimate of $1.34 million. On average, equities analysts forecast that Nabriva Therapeutics AG will post ($2.29) EPS for the current year.
About Nabriva Therapeutics AG
Nabriva Therapeutics plc is a clinical stage biopharmaceutical company. The Company is engaged in engaged in the research and development of novel anti-infectives to treat serious infections, with a focus on the pleuromutilin class of antibiotics. The Company’s medicinal chemistry has enabled targeted discovery of novel pleuromutilins, including both intravenous and oral formulations of its lead product candidate, lefamulin.
Receive News & Stock Ratings for Nabriva Therapeutics AG Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Nabriva Therapeutics AG and related stocks with our FREE daily email newsletter.